Although research in this area is still in its relative infancy (Smith et al., 2011), several key features have highlighted relaxin-3/RXFP3 systems as an attractive putative target for the treatment of cognitive deficits, and neuropsychiatric disorders, including depression. The gene discussed is RLN3; the disease is Cognitive impairment.